Komori
Presentation materials for financial results4568DAIICHI SANKYO COMPANY,LIMITEDPharmaceuticals

Supplementary Materials to Financial Results (FY2025 Results)

In FY2025, revenue and core operating profit increased, but operating profit and profit for the year declined because one-time expenses rose significantly. In FY2026, revenue, operating profit and core operating profit are expected to increase, while profit attributable to owners of the parent is expected to remain broadly flat.

Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-1028
¥100 million (year-on-year change in operating profit)
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFY2025 results (fiscal year ending March 2026)11 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales21,230 Hundreds of millions of yen+12.6%
Operating profit2,291 Hundreds of millions of yen-31.0%
Ordinary income¥2,634 100 million -25.9%profit before tax
Net income¥2,599 100 million -12.1%attributable to owners of the parent
Selling, general and administrative expenses¥8,596 100 million, selling, general and administrative expenses-to-revenue ratio 40.5%
Operating profit margin10.8%, down 6.8 percentage points year on year
Results for the three months of the current quarterFourth quarter of FY2025: revenue ¥589.6 billion, operating loss ¥4.7 billion, profit for the year ¥42.4 billion
Full-year earnings forecastFY2026: revenue ¥2,280.0 billion, operating profit ¥315.0 billion, profit before tax ¥329.0 billion, profit for the year ¥263.0 billion, profit attributable to owners of the parent ¥260.0 billion, core operating profit ¥360.0 billion
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。FY2025 actual results versus the forecast announced in October: revenue 101.1%, core operating profit 102.8%, operating profit 68.4%, profit before tax 74.2%, and profit attributable to owners of the parent 90.2%. Variances from the forecast are also provided by product and business unit.
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Foreign-exchange impact on revenue: +¥21.8 billion; on cost of sales: +¥5.7 billion; on selling, general and administrative expenses: +¥1.5 billion; and on research and development expenses: -¥0.1 billion. Main components of the ¥153.0 billion in one-time expenses in FY2025: ¥19.3 billion in impairment losses and compensation payments related to the cancellation of the Odawara investment, ¥88.3 billion in compensation for losses paid to the CMO, and ¥16.0 billion in environmental remediation costs at the former Yasu River plant.
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
FY2026 assumed exchange rates: USD/JPY 150.00 and EUR/JPY 180.00. Foreign-exchange sensitivity: a ¥1 movement would affect revenue by ¥6.5 billion for USD and ¥2.6 billion for EUR, and operating profit by -¥0.2 billion for USD and ¥0.7 billion for EUR.
Key KPIsA metric the company considers important as a management benchmark.
Overseas revenue ratio 72.7%, ROE 15.8%, DOE 8.7%, consolidated headcount 20,171
Segment results
Japan Business Unit ¥485.8 billion (up 1.9% year on year), Daiichi Sankyo Healthcare Unit ¥90.7 billion (up 4.7%), Oncology Business Unit ¥608.8 billion (up 31.3%), American Regent Unit ¥182.2 billion (down 16.1%), EU Specialty Business Unit ¥276.6 billion (up 16.5%), and ASCA Business Unit ¥251.0 billion (up 18.8%)
Financial targets
Actual ROE 15.8% and actual DOE 8.7%. Target values: not disclosed
Number of employees
20,171 consolidated employees at the end of FY2025, compared with 19,765 in the same period of the previous year
Capital expenditures
¥1,354 100 million FY2025 actual, construction basis). FY2026 forecast: ¥200.0 billion
Annual Dividend
Total dividends of ¥144.3 billion. Dividend per share and the interim and year-end breakdown: not disclosed
Payout ratio
Not disclosed. DOE was 8.7%
Acquisition of treasury shares
¥150.5 billion spent on share buybacks in FY2025. Number of shares acquired and acquisition period: not disclosed
Gross profit
¥1,681.7 billion, gross profit margin 79.2%, up 1.2 percentage points year on year
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFY2025 results (fiscal year ending March 2026)
Net Sales21,230 Hundreds of millions of yen (YoY +12.6%)
Operating profit2,291 Hundreds of millions of yen (YoY -31.0%)
Ordinary income¥2,634 100 million (profit before tax) (YoY -25.9%)
Net income¥2,599 100 million (attributable to owners of the parent) (YoY -12.1%)
Gross profit¥1,681.7 billion, gross profit margin 79.2%, up 1.2 percentage points year on year
Operating profit margin10.8%, down 6.8 percentage points year on year
Selling, general and administrative expenses¥8,596 100 million, selling, general and administrative expenses-to-revenue ratio 40.5%
Results for the three months of the current quarterFourth quarter of FY2025: revenue ¥589.6 billion, operating loss ¥4.7 billion, profit for the year ¥42.4 billion
Full-year earnings forecastFY2026: revenue ¥2,280.0 billion, operating profit ¥315.0 billion, profit before tax ¥329.0 billion, profit for the year ¥263.0 billion, profit attributable to owners of the parent ¥260.0 billion, core operating profit ¥360.0 billion
Progress against full-year forecastFY2025 actual results versus the forecast announced in October: revenue 101.1%, core operating profit 102.8%, operating profit 68.4%, profit before tax 74.2%, and profit attributable to owners of the parent 90.2%. Variances from the forecast are also provided by product and business unit.
Segment resultsJapan Business Unit ¥485.8 billion (up 1.9% year on year), Daiichi Sankyo Healthcare Unit ¥90.7 billion (up 4.7%), Oncology Business Unit ¥608.8 billion (up 31.3%), American Regent Unit ¥182.2 billion (down 16.1%), EU Specialty Business Unit ¥276.6 billion (up 16.5%), and ASCA Business Unit ¥251.0 billion (up 18.8%)
Breakdown of Factors Affecting the ChangeForeign-exchange impact on revenue: +¥21.8 billion; on cost of sales: +¥5.7 billion; on selling, general and administrative expenses: +¥1.5 billion; and on research and development expenses: -¥0.1 billion. Main components of the ¥153.0 billion in one-time expenses in FY2025: ¥19.3 billion in impairment losses and compensation payments related to the cancellation of the Odawara investment, ¥88.3 billion in compensation for losses paid to the CMO, and ¥16.0 billion in environmental remediation costs at the former Yasu River plant.
Key KPIsOverseas revenue ratio 72.7%, ROE 15.8%, DOE 8.7%, consolidated headcount 20,171
Number of employees20,171 consolidated employees at the end of FY2025, compared with 19,765 in the same period of the previous year
Assumptions Underlying the Business OutlookFY2026 assumed exchange rates: USD/JPY 150.00 and EUR/JPY 180.00. Foreign-exchange sensitivity: a ¥1 movement would affect revenue by ¥6.5 billion for USD and ¥2.6 billion for EUR, and operating profit by -¥0.2 billion for USD and ¥0.7 billion for EUR.
Financial targetsActual ROE 15.8% and actual DOE 8.7%. Target values: not disclosed
Annual DividendTotal dividends of ¥144.3 billion. Dividend per share and the interim and year-end breakdown: not disclosed
Payout ratioNot disclosed. DOE was 8.7%
Acquisition of treasury shares¥150.5 billion spent on share buybacks in FY2025. Number of shares acquired and acquisition period: not disclosed
Capital expenditures¥1,354 100 million (FY2025 actual, construction basis). FY2026 forecast: ¥200.0 billion
Items this document does not state (9)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company states that the decline in operating profit in FY2025 reflected ¥153.0 billion in one-time expenses, including impairment losses and compensation payments related to the cancellation of the Odawara investment, compensation for losses paid to a CMO, and environmental remediation costs at the former Yasu River plant. In FY2026, compensation for losses paid to the CMO is expected to decline from ¥169.5 billion to ¥80.0 billion, among other factors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Materials to Financial Results (FY2025 Results) | DAIICHI SANKYO COMPANY,LIMITED (4568) timely disclosure | Komori